Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + Dexamethasone in R/R B-cell ALL
NCT03472573Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2018
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of palbociclib in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Incidence of dose limiting toxicities at 28 days and Maximum tolerated dose at 28 days. Started May 2018; status: completed.
02
Drugs
palbociclib
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03472573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472573.